Indications

• Bleeding in Presence of Hyperfibrinolysis (see Hyperfibrinolytic States, [[Hyperfibrinolytic States]])
• Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency (see Plasminogen Activator Inhibitor-1 Deficiency, [[Plasminogen Activator Inhibitor-1 Deficiency]])
• Von Willebrand Disease (see Von Willebrand Disease, [[Von Willebrand Disease]])

Pharmacology

• Anti-Fibrinolytic (see Anti-Fibrinolytics, [[Anti-Fibrinolytics]]): lysine analogue which binds to kringle domains of plasminogen, disrupting interaction between plasminogen (and plasmin) and lysine residues within fibrin
  • Tranexamic Acid (see Tranexamic Acid, [[Tranexamic Acid]]): binds plasminogen (and plasmin) 8x more avidly than the older epsilon aminocaproic acid analogue -> may exert a more potent anti-hemorrhagic effect

Administration

• IV

Adverse Effects

Other Adverse Effects

• xxx
• xxx
• xxx

References

• xxxx
  s